Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study

NCT07516704 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy

Sponsor

Zhongda Hospital